Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
MWN-AI** Summary
Agenus Inc. (Nasdaq: AGEN), a prominent player in the immuno-oncology sector, has announced that it will release its financial results for the fourth quarter and full year 2025 on March 16, 2026, prior to market opening. Following this release, the company will conduct a stakeholder briefing webcast later in March, which aims to provide insights into crucial strategic initiatives, significant data milestones, and updates concerning the global development of its drug candidates, botensilimab (BOT) and balstilimab (BAL).
Founded in 1994 and based in Lexington, Massachusetts, Agenus focuses on expanding the applicability of cancer immunotherapy through its extensive array of immunological therapies, including antibody therapeutics and adoptive cell therapies through its partnership with MiNK Therapeutics. The company boasts comprehensive development capabilities, from clinical and commercial-grade manufacturing to global research operations.
Botensilimab is a multifunctional anti-CTLA-4 antibody engineered to enhance both innate and adaptive anti-tumor immune responses. It aims to treat “cold” tumors, which typically show limited responses to existing therapies. Data from ongoing clinical trials indicate promising efficacy, including responses across multiple types of late-stage metastatic cancers, with around 1,200 patients already treated.
Balstilimab, another investigational product, is a monoclonal immunoglobulin designed to inhibit PD-1, a target critical in tumor immune evasion. It has shown clinical effectiveness and an acceptable safety profile in over 900 patients across various tumor types.
Investors are cautioned that forward-looking statements in the press release involve inherent risks and uncertainties, suggesting the need for due diligence in interpreting the company’s future performance projections.
MWN-AI** Analysis
Agenus Inc. (Nasdaq: AGEN), a prominent player in the immuno-oncology space, is gearing up to release its fourth quarter and year-end financial results for 2025 on March 16, 2026. As anticipation builds around this important update, investors should consider several factors when evaluating the company's market position and future prospects.
Agenus has developed a strong pipeline centered around its lead assets, botensilimab (BOT) and balstilimab (BAL), both of which target challenging tumor types that have shown low response rates to conventional therapies. With approximately 1,200 patients treated in ongoing clinical trials, the efficacy of botensilimab as a multifunctional anti-CTLA-4 antibody could prove pivotal in expanding the company's market share. The late March stakeholder briefing will likely be a key event where management discusses strategic plans and updates on these assets, which will be crucial for gauging future performance.
Investors should closely monitor the data released in the upcoming financial report as it will provide insights into the company's revenue trajectory, R&D expenditure, and cash runway. Furthermore, regulatory milestones will be of great importance; any upcoming filings for BOT and BAL could significantly influence stock performance.
Moreover, Agenus' capabilities in manufacturing and global clinical operations position it well in a competitive landscape. However, the market can be fickle in biotech, particularly with the inherent risks associated with clinical trials.
In summary, investors should approach Agenus with a watchful eye, assessing the implications of the forthcoming results and updates. The company's underlying technology and diversified pipeline offer potential, but prospective buyers should remain aware of the volatility typical of biotech stocks. Caution is advised until clearer indicators of regulatory progress and clinical success emerge.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Agenus Inc. (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.
Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
About Botensilimab (BOT)
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov .
About Balstilimab (BAL)
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Source: Agenus Bio
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304473547/en/
Investors : 917-362-1370 | investor@agenusbio.com
Media: 781-674-4422 | communications@agenusbio.com
FAQ**
What specific data milestones related to botensilimab (BOT) and balstilimab (BAL) can investors expect to hear about during the upcoming stakeholder briefing for Agenus Inc. AGEN in late March 2026?
How does Agenus Inc. AGEN plan to address potential risks and uncertainties mentioned in their most recent Annual Report on Form 10-K that could impact the botensilimab and balstilimab development programs?
Can you provide more details on the patient populations being targeted by Agenus Inc. AGEN with the use of botensilimab (BOT) to treat "cold" tumors that typically have poor responses to existing therapies?
What are the anticipated regulatory timelines and next steps for Agenus Inc. AGEN regarding the submission of investigational new drug applications for botensilimab and balstilimab following the upcoming financial results release?
**MWN-AI FAQ is based on asking OpenAI questions about Agenus Inc. (NASDAQ: AGEN).
NASDAQ: AGEN
AGEN Trading
11.13% G/L:
$3.51 Last:
455,044 Volume:
$3.21 Open:
